Keywords: amrad, signs, 50m, deal, gsk, australian, bio-research
Amrad signs $50M R&D deal with GSK
Article | 19 February 2001
Australian bio-research company Amrad Corp has signed an exclusive R&Dcollaboration and license agreement with GlaxoSmithKline. The multi-year deal involves ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
